Pancreatic Neoplasm

Oncology
5
Pipeline Programs
4
Companies
2
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

Regeneron
EYLEAApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2011
Regeneron
EYLEA HDApproved
aflibercept
Regeneron
Vascular Endothelial Growth Factor Inhibitor [EPC]injection2023

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Regeneron
RegeneronTARRYTOWN, NY
1 program
1
1
AfliberceptPhase 3
Sanofi
SanofiPARIS, France
1 program
1
AfliberceptPhase 31 trial
Active Trials
NCT00574275Terminated546Est. Nov 2010
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
enzastaurinPhase 21 trial
Active Trials
NCT00267020Completed130Est. May 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiAflibercept
Eli Lilly and Companyenzastaurin

Clinical Trials (2)

Total enrollment: 676 patients across 2 trials

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

Start: Dec 2007Est. completion: Nov 2010546 patients
Phase 3Terminated

Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

Start: Dec 2005Est. completion: May 2008130 patients
Phase 2Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space